Kyogoku unyu shoji
9073
BlueMeme
4069
Estore
4304
Visumo
303A
D. Western Therapeutics Institute
4576
JP Stock MarketDetailed Quotes
4574 Taiko Pharmaceutical
- 331
- -1-0.30%
20min DelayMarket Closed Dec 30 15:30 JST
16.76BMarket Cap-4.34P/E (Static)
336High327Low168.50KVolume336Open332Pre Close55.84MTurnover49552wk High0.54%Turnover Ratio50.64MShares28552wk Low-49.65EPS TTM10.38BFloat Cap2928Historical HighLossP/E (Static)31.37MShs Float197Historical Low-76.25EPS LYR2.71%Amplitude--Dividend TTM2.06P/B100Lot Size--Div YieldTTM
Taiko Pharmaceutical News
List of Conversion Stocks (Part 1) [List of Parabolic Signal Conversion Stocks]
○ List of stocks for Buy conversion Market Code Stock Name Closing Price SAR Main Board <1419> Tamahome 3470 3400 <1605> INPEX 19881924 <1663> K&O Energy 32602960 <1821> Mitsui Construction 422411 <1852> Asanuma Corporation 627613 <1898> Seiki Tokyu 15051462 <2117> Wellneo S 21452117 <2209> Imuraya
Taiko Pharmaceutical 9-Mos Net Y714.00M Vs Loss Y562.00M
Taiko Pharmaceutical: Consolidated financial results report for the 3rd quarter of the fiscal year ending 2024/12 (FY2024)
Taiko Pharmaceutical: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [Japanese GAAP] (consolidated)
Morinaga Milk, mcdonald's, Toyo Suisan, Eisai (8th) (1429-5463)
※Please note that the above calendar is tentative and subject to change based on the company's convenience. --------------------------------------- November 8th (Fri) <1429> Japan Aqua <1435> RoboHome <143A> Ishin <1450> Tanaka Construction Industry <1451> KHC <1518> Mitsui Matsushima HD <151A> Dai <167A> Ryo
Daiko Pharmaceuticals Research Memo (3): Change of policy to a two-factory production system for the pharmaceutical business. "Cleverin" targets students preparing for examinations.
■ DaiKo Yakuhin <4574> Topics 1. Pharmaceutical business: Strengthening supply capacity, smooth progress in price increases. The external environment of the pharmaceutical business is favorable. The increase in opportunities to go out and the demand from inbound visitors are tailwinds, and the domestic anti-diarrhea market is surpassing pre-COVID-19 levels. The stable supply from the company has been key to expanding market share, and efforts have been made to strengthen the shift production system at the Suita and Oguni factories, as well as to launch the packaging line for 'Seirogan Sugar Coated A' at the Kyoto factory.
Daiko Pharmaceutical Research Memo (2): Increased revenue and profit for the fiscal year ending December 2024. Revised upward forecast for operating and ordinary profit.
For the fiscal year ending December 2024, we expect revenue of 6,800 million yen (an increase of 11.1% compared to the previous year), operating profit of 550 million yen (a loss of 1,005 million yen in the previous year), ordinary profit of 590 million yen (a loss of 1,248 million yen in the previous year), and net income attributable to the parent company shareholders of 550 million yen (a loss of 3,611 million yen in the previous year).
Daiko Pharmaceuticals Research Memo (1): Achieved profitability for the first time in four quarters in the second quarter of the fiscal year ending December 2024.
Daiko Yakuhin Co., Ltd. <4574> operates a pharmaceutical business centering on products such as "Seirogan" and "Seirogan Sugar-coated A" and an infectious control business centering on the "Cleverin" series of virus removal, sterilization, and deodorization products. In the second quarter of the fiscal year ending December 2024, revenue was 286 billion yen (a 14.9% increase from the same period last year), operating profit was 482 million yen (a loss of 396 million yen in the same period last year), ordinary profit was 528 million yen (a loss of 510 million yen in the same period last year), and net profit attributable to the parent company's shareholders was.
Taiko Pharmaceutical: Consolidated financial statements for the second quarter (interim period) of the fiscal year ending December 2024 (FY2024).
Daiko Yakuhin: Double-digit revenue growth in the second quarter, with each stage of profit turning black. The pharmaceutical business is progressing smoothly in terms of both revenue and profit.
On the 9th, Daiichi Kosei Pharma <4574> released its consolidated financial results for the second quarter of the fiscal year ending December 2024 (January-June 2024). Revenue increased by 14.9% from the same period of the previous year to 2.86 billion yen, operating profit was 0.482 billion yen (compared to a loss of 0.396 billion yen in the same period of the previous year), ordinary profit was 0.528 billion yen (compared to a loss of 0.51 billion yen in the same period of the previous year), and the net profit attributable to the shareholders of the parent company for the interim period was 0.764 billion yen (compared to a loss of 0.514 billion yen in the same period of the previous year). Revenue from the pharmaceutical business increased by 25.5% compared to the same period of the previous year, reaching 2.654 billion yen, with a segment profit.
Daiko Yakuhin - Revision of consolidated performance estimates and recording of impairment losses in the pharmaceutical business.
Daiko Yakuhin <4574> has revised its consolidated earnings forecast for the fiscal year ending December 2024 and has decided to reorganize its production system in its pharmaceutical business. Revenue will remain unchanged from the previous forecast at 6.8 billion yen, and operating profit will increase by 34.1% compared to the previous forecast to 0.55 billion yen. Ordinary profit will increase by 63.9% to 59 billion yen, and net income attributable to shareholders of the parent company will remain unchanged at 0.55 billion yen. In terms of revenue, the pharmaceutical business is expected to progress largely as planned due to steady demand.
Taiko Pharmaceutical Posts Robust Financial Recovery
Taiko Pharmaceutical: Confirmatory letter.
Taiko Pharmaceutical: Interim Report - 79th period (January 1, 2024 - December 31, 2024)
Taiko Pharmaceutical: Announcements of individual stocks regarding the revision of consolidated performance estimates and the restructuring of production system in pharmaceutical business (recognition of impairment losses).
Taiko Pharmaceutical: 2024 December Q2 (Interim) Financial Results (Japan Standard) (Consolidated)
List of Cloud Breakout Stocks [Ichimoku Balance Table, List of Cloud Breakout Stocks]
- Cloud-based stock ranking market Code Name End Price Leading Span A Leading Span B TOKYO PRIME 2157 Koshidaka Holdings 879 853.25 875 2175 SMS Co., Ltd. 2076 1983.5 2067.5 2264 Morinaga Milk Industry Co., Ltd. 3407 3321 3248.5 2379 Dip Details Stay tuned for future updates!
McDonald's, Isetan Mitsukoshi, Rakuten G, ENEOS HD (9th) (1379-5076)
*The calendar above is tentative and subject to change due to company circumstances. ---------------------------------------August 9 (Friday) <1379> Hokuto <1381> Access <1384> Hokuriyo <1414> Showbond <1417> Miraito One <1429> Japan Aqua <142A> Gingerbread <1431> Livework <14
List of stocks with cleared clouds (Part 2) [Ichimoku Kinko Hyo: List of Stocks with Cleared Clouds]
- List of stocks that broke through below the cloud Market Code Name Closing Price Leading Span A Leading Span B Tokyo Stock Exchange Prime ＜4099＞ Shikoku Chemicals 1731 2059.25 1899 ＜4188＞ Mitsubishi Chemicals 744 848 861.5 ＜4194＞ Visional 6780 7165 7410 ＜4272＞
Stocks that moved the day before, Part 1: Cell Source, Toho, Kawasaki Heavy Industries, etc.
Stock name
, 17-day closing price ⇒ change from previous day. Advantest<6857> 6361 -167 is reported to consider the use of the toughest trade restriction measures against China's semiconductor regulations. Floint<6312> 842 -59 had an operating loss of 0.264 billion yen in the first quarter. Teitz<7610> 109 -7 operating profit decreased by 76.3% in the first quarter. SIGG <4386> 673 +100 partnered with cutting-edge AI development startup. EnergyChange<4169> 478.